KEITH LEMAY: Open Payments
NPI 1922379759 · SOUTH LAKE TAHOE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 27 payments from 15 companies in 2025. Trend: 2023 $158 · 2024 $315 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| BridgeBio Pharma, Inc. | 1 | $138 |
| Novartis Pharmaceuticals Corporation | 3 | $86 |
| GlaxoSmithKline, LLC. | 4 | $77 |
| PFIZER INC. | 3 | $57 |
| Astellas Pharma US Inc | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Edwards Lifesciences Corporation | 1 | $33 |
| Lilly USA, LLC | 2 | $30 |
| ABBVIE INC. | 1 | $23 |
Products named: Attruby, LEQVIO, TRELEGY ELLIPTA, PREVNAR 20, Veozah, REXULTI, CAPLYTA, SAPIEN 3 Ultra RESILIA.
Industry payments across CA — which companies pay providers there.
